Financial News
Latest News about RHHBY
Recent news which mentions RHHBY
Why Are ImmunoGen Shares Trading Lower Today
March 21, 2022
From Benzinga
Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population
March 16, 2022
From Benzinga
2 Top Stocks to Buy in March and Hold Forever
March 15, 2022
From Motley Fool
The OTCQX's Top 10 Experience A Shuffle In February
March 15, 2022
From Benzinga
From Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
March 15, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Motley Fool
Viatris Just Snagged a Major FDA Approval
March 03, 2022
From Motley Fool
2 Biotech Stocks That Could Make You Richer
March 02, 2022
From Motley Fool
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
February 22, 2022
From Benzinga
From Benzinga
3 Cutting-Edge, Protein-Degrader Biotech Stocks to Watch
February 16, 2022
From Motley Fool
These OTC Securities Reported The Most Trading Volume In January – With Possible Sustained Interest In International Operators
February 14, 2022
From Benzinga
Why Are Seagen Shares Sinking Today?
February 10, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
From Benzinga
From Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
February 03, 2022
From Benzinga
From Benzinga
Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
February 02, 2022
From Benzinga
Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab
February 01, 2022
From Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
From Benzinga
FDA Approves First Injectable Eye Medicine For Vision Loss Disorder - Genentech's Vabysmo
January 31, 2022
From Benzinga
Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months
January 25, 2022
From Benzinga
These OTC Securities Had the Most Trading Activity in December
January 25, 2022
From Benzinga
3 Clinical Trials to Watch in the First Half of 2022
January 22, 2022
From Motley Fool
2 Risky Growth Stocks That Could Make You Filthy Rich
January 16, 2022
From Motley Fool
Where Will Biogen Be in 5 Years?
January 15, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
